Back to results
US 2026/0265290 A1Published application
3-alpha substituted 3-beta-hydroxy-17-oximated androstane compound for modulation of the alpha-3 subtype of the gabaa receptor
AssigneeUmecrine Cognition AB
InventorsTorbjörn Bäckström, Gianna Ragagnin, Jessica Sjöstedt
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a compound, 3α-ethynyl-3β-hydroxy-5α-androstan-17-methoxime, as shown in Formula 1: or pharmaceutically acceptable salts thereof, which is useful for the modulation of the α-3 subtype of the GABAA receptor, and in the treatment of a variety of disorders or diseases associated therewith.
Claims6
A compound, 3α-ethynyl-3β-hydroxy-5α-androstan-17-methoxime, as shown in Formula 1
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.